Related Experiment Video
Updated: Jul 1, 2026

Malachite Green Assay for the Discovery of Heat-Shock Protein 90 Inhibitors
Published on: January 20, 2023
A novel class of small molecule inhibitors of Hsp90
1Department of Molecular Biophysics & Biochemistry, Yale University, 266 Whitney Avenue, New Haven, Connecticut 06520, USA.
Abstract:
Unregulated cellular proliferation, caused by mutation or dysregulation of growth-promoting proteins, is an underlying cause of cancer. Many such growth-promoting proteins exhibit an increased dependence on the activity of the chaperone heat-shock protein 90 (Hsp90) for correct folding and maturation in the cell. One can therefore envision that inhibition of Hsp90 would be an effective and broadly applicable strategy for the development of anticancer agents. Hsp90 functions in multichaperone complexes driven by the binding and hydrolysis of ATP. Encouraging results have been obtained by inhibiting Hsp90 with 17-AAG, an active-site binding ATP analog. Here we present the results of a different approach to inhibiting Hsp90 by disrupting its interaction with a cochaperone named Hsp organizing protein (HOP). We have used an AlphaScreen technology based high-throughput in vitro screen to identify compounds that inhibit this interaction. In addition, we demonstrate that these compounds are active in vivo. Treatment of human breast cancer cell lines BT474 and SKBR3 with these compounds decreases the levels of the Hsp90-dependent client protein HER2, with associated cell death.
Insights
Researchers identified compounds that disrupt heat-shock protein 90 (Hsp90) interactions with its cochaperone HOP. This novel approach inhibits cancer cell growth by reducing Hsp90-dependent proteins like HER2, leading to cell death.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Unregulated cellular proliferation drives cancer, often involving growth-promoting proteins dependent on heat-shock protein 90 (Hsp90).
- Hsp90 is crucial for the folding and maturation of these client proteins, making it a potential therapeutic target for cancer treatment.
- Existing strategies involve inhibiting Hsp90 directly with ATP analogs like 17-AAG.
Purpose of the Study:
- To explore a novel strategy for inhibiting Hsp90 by disrupting its interaction with the cochaperone Hsp organizing protein (HOP).
- To identify small molecules that inhibit the Hsp90-HOP interaction using a high-throughput screening method.
- To evaluate the in vitro and in vivo efficacy of these identified compounds as anticancer agents.
Main Methods:
- Utilized AlphaScreen technology for a high-throughput in vitro screen to identify compounds inhibiting the Hsp90-HOP interaction.
- Tested the identified compounds for their ability to decrease Hsp90-dependent client proteins in human breast cancer cell lines.
- Assessed the impact of compound treatment on cancer cell viability and proliferation.
Main Results:
- Successfully identified compounds that inhibit the Hsp90-HOP interaction in vitro.
- Demonstrated that these compounds are active in vivo, reducing levels of the Hsp90 client protein HER2 in BT474 and SKBR3 breast cancer cells.
- Observed associated cancer cell death following treatment, indicating therapeutic potential.
Conclusions:
- Disrupting the Hsp90-HOP interaction represents a viable and distinct strategy for Hsp90 inhibition in cancer therapy.
- The identified compounds show promise as novel anticancer agents targeting Hsp90-dependent pathways.
- This approach offers a potentially broader applicability compared to direct Hsp90 active-site inhibition.
More Related Videos
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Inhibitors of Bacterial Protein Synthesis
Molecular Chaperones and Protein Folding
The...
Molecular Chaperones and Protein Folding
The...
Inhibitors Of Virion Release
Inhibitors of Virion Maturation and Assembly

